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Correspondence
Response to Letter Regarding Article, “Triple
Versus Dual Antiplatelet Therapy in Patients With
Acute ST-Segment Elevation Myocardial
Infarction Undergoing Primary Percutaneous
Coronary Intervention”
We thank Lin et al for their interest in our article1 and for raising
some concerns. They suggested that the advantage of triple antiplate-
let therapy in short-term outcomes should be emphasized in higher-
risk patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention.
We totally agree with their opinion, and our article also has shown
that the clinical benefit of adjuvant cilostazol was profound from the
earlier period, especially within 1 month. In the subgroup analyses of
our study,1 we found that older (65 years of age), female, and
diabetic patients got more benefit from triple antiplatelet therapy
than their counterparts who received dual antiplatelet therapy. These
findings are consistent with previous studies.2
The present study showed that more patients in the triple group
received glycoprotein IIb/IIIa receptor blockers than those in the dual
group. But our multivariable Cox regression analysis revealed that
glycoprotein IIb/IIIa receptor blockers were not an independent
predictor of clinical outcomes at 8 months. In contrast to the studies
by De Luca et al,3 which enrolled randomized trials using abciximab
as adjunctive therapy to reperfusion in acute STEMI, our study came
from a prospectively designed registry reflecting real-world clinical
practice in the era of drug-eluting stents. Currently, only abciximab
is commercially available in Korea, and we suppose the inconsistent
use of glycoprotein IIb/IIIa receptor blockers might have influenced
their efficacy in the present study. However, we used a propensity
score–adjusted multivariable Cox regression analysis, which con-
tained glycoprotein IIb/IIIa receptor blockers as a coanalytic factor,
and our results showed that the adjunctive cilostazol remained
beneficial independently from other confounders.
As Dr Lin and colleagues have mentioned, the coadministration of
calcium channel blockers is associated with decreased platelet
inhibition by clopidogrel.4 Angiotensin-converting enzyme inhibi-
tors may attenuate the antiplatelet effects of aspirin.5 We agree that
the interactions between these 3 drugs may exist. However, in the
present study, patients in the triple group were more likely to receive
angiotensin-converting enzyme inhibitors, whereas they were less
likely to receive calcium channel blockers. Therefore, the interac-
tions might have been offset by the inverse use of angiotensin-
converting enzyme inhibitors and calcium channel blockers between
the 2 compared groups. Furthermore, the propensity score–adjusted
multivariable Cox regression analysis might have helped us mini-
mize these interactions.
The concerns relative to stent thrombosis had not been proposed at
the end of 2005 in the Korea Acute Myocardial Infarction Registry.
Thus, when we initiated the Korea Acute Myocardial Infarction
Registry study, stent thrombosis wasn’t recorded. However, when
the issue of stent thrombosis with drug-eluting stents was raised at
the end of 2006, we started to record stent thrombosis and associated
clinical events. Therefore, in the Korea Acute Myocardial Infarction
Registry study, only half of the patients have stent thrombosis
information. In the present study, because we enrolled all of the
patients who underwent primary percutaneous coronary intervention
with drug-eluting stents, we could not calculate the exact incidence
of stent thrombosis. We are planning to carry out a randomized
clinical trial to clarify the optimal duration and mechanisms of
benefit from triple antiplatelet therapy. We hope our further study
can answer the concerns of Dr Lin et al.
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